Abbonarsi

HEPATITIS C - 09/09/11

Doi : 10.1016/S0891-5520(05)70405-0 
Miriam J. Alter, PhD *, Eric E. Mast, MD, MPH *, Linda A. Moyer, BS *, Harold S. Margolis, MD *

Riassunto

Since its discovery in 1988,25 hepatitis C virus (HCV) has emerged as a major cause of chronic liver disease worldwide. The widespread endemicity of HCV infection is the result of a combination of factors, including those related to the genetic diversity of the virus and the host response, and specific settings and behaviors that facilitated transmission.

The vast majority of persons who contract HCV infection become persistently infected, and most also develop chronic liver disease, including cirrhosis and hepatocellular carcinoma. The mechanism by which such a high rate of persistent infection is established appears to be related to the lack of development of an effective neutralizing immune response. Like other RNA viruses, the substantial heterogeneity of the HCV genome is the result of mutations that occur during viral replication.19 Within an infected individual, the genetic heterogeneity of HCV consists of a population of closely related, yet heterogeneous, sequences called quasispecies, which result from the rapid development of mutations in a hypervariable region (HVR1) within one of the envelope proteins. Patients infected with HCV mount a humoral immune response to epitopes of HVR1, but sequential changes in the consensus sequence of HVR1 during infection result in the generation of variants that are not recognized by preexisting antibodies.19, 38, 39, 83 The generation of these neutralization escape mutants appears to be the mechanism by which the virus establishes and maintains persistent infection.

Although virus- and host-specific factors are responsible for the high rate of chronic HCV infection, the magnitude of the spread of HCV infection is primarily the result of specific factors related to transmission. Historically, healthcare-related factors that have been important in the transmission of HCV included the transfusion of contaminated blood and blood products and the reuse or sharing of contaminated equipment during the course of both traditional and nontraditional medical procedures. The most important human behavior related to the transmission of HCV has been injection drug use, which in many developed countries has been the leading source of HCV infection during the past 20 to 30 years.

The clinical importance of HCV infection was recognized only recently, and attention and resources have been rapidly directed toward developing new and improved therapies. The perception of the public health importance of HCV infection is still limited. Despite the knowledge that injection drug use is the major source of HCV infection in the United States, this message has not been included in prevention and treatment programs, and the resources needed to support strong public health programs have yet to be identified.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Address reprint requests to Miriam J. Alter, PhD, Hepatitis Branch, Mailstop G37, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333


© 1998  W. B. Saunders Company. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 12 - N° 1

P. 13-26 - marzo 1998 Ritorno al numero
Articolo precedente Articolo precedente
  • CYCLOSPORA
  • Rosemary Soave, Barbara L. Herwaldt, David A. Relman
| Articolo seguente Articolo seguente
  • INFLUENZA
  • Nancy J. Cox, Keiji Fukuda

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.